Abstract
A 56-year-old white man with a 74 pack-year smoking history presented with macroscopic hematuria and a significant weight loss of 45 pounds in 6 months. His clinical laboratory tests indicated iron defi ciency anemia and a computed tomography (CT) scan showed a left kidney tumor, mediastinal lymph nodes, and multiple lung metastases. A percutaneous CT-guided kidney biopsy revealed grade 3 clear cell renal carcinoma based on World Health Organization/International Society of Urologic Pathology classifi cation. The patient started first line systemic treatment for intermediate-risk metastatic renal cell carcinoma (mRCC) with combination immunotherapy with nivolumab plus ipilimumab.1 After 10 days of the first cycle, he presented with a pruritic maculopapular rash covering 20% of his body surface.
MeSH terms
-
Anti-Inflammatory Agents / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / immunology
-
Carcinoma, Renal Cell / pathology
-
Humans
-
Immunotherapy / methods
-
Ipilimumab / administration & dosage
-
Ipilimumab / adverse effects
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / immunology
-
Kidney Neoplasms / pathology
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / immunology
-
Lung Neoplasms / secondary
-
Lymphatic Metastasis
-
Male
-
Middle Aged
-
Nephritis, Interstitial / chemically induced
-
Nephritis, Interstitial / drug therapy
-
Nephritis, Interstitial / pathology
-
Nivolumab / administration & dosage
-
Nivolumab / adverse effects
-
Prednisone / administration & dosage
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents
-
Ipilimumab
-
Nivolumab
-
Prednisone